J&J inks another Stelara biosimilar settlement, pushing Formycon’s candidate into potential 2025 launch

Another biosimilar version of Johnson & Johnson’s Stelara has been delayed after the pharma giant inked a new agreement with two European drugmakers developing a biosimilar version of J&J’s top-selling drug.

Formycon and Fresenius Kabi announced the settlement Monday morning, saying that their experimental biosimilar candidate to Stelara is set to be launched in the US by April 15, 2025.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

FDA rejects Intercept’s NASH drug, prompting a pivot

The Food and Drug Administration rejected Intercept Pharmaceuticals’ investigational treatment for NASH on Thursday, derailing what would have been the first approved medicine for a

June 22, 2023

RSV vaccines may be linked to small increased risk of developing Guillain-Barré syndrome, data suggest

The new vaccines that protect older adults against respiratory syncytial virus, or RSV, may be linked to a small increased risk of developing Guillain-Barré syndrome,

February 29, 2024

Departing Stanford president retracts two widely cited papers, against lead author’s wishes

After an expansive investigation found manipulated data and other issues with papers co-authored by Stanford’s now ex-president Marc Tessier-Lavigne, the prominent neuroscientist on Thursday retracted

August 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.